Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AH Trading $.0947 +0.0018 +1.94%
No share price manipulation here. LOL
Enjoy dp
http://www.nasdaq.com/symbol/asti/after-hours
AH Time AH Price AH Volume
16:46 $ .0947 High 1,499
16:03 $ .0947 1
16:01 $ .0889 Low 646,161
NFL Head Injury Claims
Well, it seems that your comment on the lawyers getting involved was spot on there CnW.
Attention NFL Players!
The NFL® has agreed to pay former players suffering from head injuries - Billions of Dollars!
See the link below for all the details.
Enjoy dp
http://nflinjurycenter.com/
KYROS LAW GROUP
Right now, the National Football League, NFL®, is one of the most popular sports in the United States. The NFL® makes billions of dollars annually and some players may be sacrificing their long-term health and livelihoods for the profitability of the game. Even with significant medical evidence that concussions and repeated blows to the head can lead to serious long-term health problems, we believe that some players were not adequately informed by the NFL® of the potential health risks. While retired NFL® players have suffered for years with cases of dementia, reduced mental capacity, mental illness, and other serious health problems, the league is just now starting to acknowledge the long term adverse effects of repeated head trauma.
A recent study conducted at Boston University's Center for the Study of Traumatic Encephalopathy discovered evidence that a condition called chronic traumatic encephalopathy (CTE), a severe degenerative brain disease, had been found in the brains of 87 of 91 deceased former NFL® players. Their cases shared a common thread: repeated concussions, sub-concussive blows to the head, or both, according to the study. CTE is characterized by a progressive deterioration in mental capabilities. It begins with mild memory loss and lessened concentration, and can progress towards symptoms of Parkinson’s disease to full-blown dementia and speech abnormalities.
Exactly as I see it - Foreign trade
Learning and researching is better than much of the Guessing?? and nonfactual "thinking" that proliferates here and everywhere...
Appreciate and find interest in your posts Hei5enberg
Have done much search on HDD broker and it appears always Forex market comes up with (NDD) meaning No Dealing Desk.
Taking those two terms into consideration it seems to me that the answer is that these NDD trades are done in foreign currency which requires Forex exchange to convert to USD and are done by a NDD that is a broker with No Dealing Desk.
See the definitions below and Please realize that I don't KNOW but am trying to HELP in figuring out WHAT? is going on with the trades you are indicating.
Maybe someone else with additional knowledge and information can elaborate.
Hope this Helps and is somewhat correct in explaining these trades.
Best to you. dp
FOREX
The foreign exchange market (forex, FX, or currency market) is a global decentralized market for the trading of currencies. This includes all aspects of buying, selling and exchanging currencies at current or determined prices. In terms of volume of trading, it is by far the largest market in the world.
DEFINITION of 'No Dealing Desk' (NDD)
A way of forex trading that provides immediate access to the interbank market. The interbank market is where foreign currencies are traded. This is different than trading through the dealing desks that are found in many banks and financial institutions. By using a dealing desk, a forex broker who is registered as a Futures Commission Merchant (FCM) and Retail Foreign Exchange Dealer (RFED) can offset trades. If a no dealing desk system is used, positions are automatically offset and then transmitted directly to the interbank.
There are no updates when there is nothing to update
Nothing is wrong with your understanding or the website. Just nothing has changed for ASTI is what the reality is.
NASDQ decides and then announces. There is no "holding news back". Doesn't and can't possibly work that way.
Ascent Solar Technologies, Inc.
ASTI Bid Price NCM 6/18/2015
ASTI MV of Security NCM 6/9/2015
A good question to Ask is: Who is buying all these traded shares anyway?
It's not just the volume of retail flippers. Think about it...
Enjoy dp
No one here really knows What? or When?
And whatever it is, stranger things are known to happen. Just look at the last NASDQ stock that was delisted:
Horsehead Holding Corp. ZINC Regulatory/Non Compliance Suspended 2/11/2016
ZINC traded @ around .10 before announced . ZINCQ opened at .07 on OTC 2/11/16 and hit a high of .34 this morning before pulling back to around .26 now.
Not saying anything above relates to ASTI in any way, shape or form but just showing that anything can (and often will) happen...
Enjoy dp
Upsurge in paralysis condition accompanies Zika virus
From yesterday. See link below for video.
http://news.yahoo.com/doctors-upsurge-paralysis-condition-accompanies-050831706.html
Doctors: Upsurge in paralysis condition accompanies Zika
Associated Press By FRANK BAJAK and LIBARDO CARDONA
CUCUTA, Colombia (AP) — The doctor taps Zulay Balza’s knees with a hammer and she doesn’t feel a thing. She can’t squeeze his outstretched fingers or shut her eyelids. Her face is partially paralyzed.
“The weakness started in my legs and climbed upward. The face was last. After three days, I couldn’t walk,” said Balza, 49. “My legs felt like rags.”
Balza is a patient at the public University Hospital in Cucuta, at the epicenter of the Colombian outbreak of the mosquito-borne Zika virus. Only Brazil has more cases.
Two weeks ago, she came under assault by Guillain-Barre (gee-YOHN-bah-RAY), a rare and sometimes fatal affliction that is the Western world’s most common cause of general paralysis.
Alarm over the Zika epidemic spreading across the Americas has been chiefly over birth defects, but frontline physicians believe a surge in Guillain-Barre cases may also be related.
The World Health Organization says Guillain-Barre cases are on the rise in Brazil, Colombia, El Salvador, Suriname and Venezuela, all hit hard by Zika, though a link remains unproven.
The auto-immune disorder historically strikes only one or two people in 100,000. About one in 20 of those cases ends in death in the developed world, and it is frightful.
“I thought my body was going to explode,” said Balza, sitting on her hospital bed and apparently over the worst.
Guillain-Barre attacks skeletal muscular nerves as if they were a foreign enemy. Fine motor skills rapidly erode, arms and legs tingle and weaken to numbness. Patients lose their balance, their speech. In rare cases, they require ventilators to stay alive.
The syndrome typically strikes after a bacterial or viral infection, such as influenza, HIV or dengue, though its cause can’t always be determined.
Dr. Jairo Lizarazo, the neurologist treating Balza, has seen cases increase more than tenfold since December — 30 cases in all — in this muggy city bordering Venezuela. Like Balza, many patients never showed the characteristic symptoms of Zika — fever, rashes, joint pain and conjunctivitis. Four in five don’t.
He’s convinced the virus boosts susceptibility to Guillain-Barre.
“It’s an epidemiological association,” said Lizarazo. “We don’t know exactly how it works. But it’s there, for sure.”
Associated cases confirmed or suspected based on clinical evidence number in the hundreds. Guillain-Barre cases believed to be linked to the virus have killed three people in recent weeks in Colombia and health officials have attributed another three Guillian-Barre deaths in Venezuela to suspected Zika infections.
WHO said Zika has been confirmed present in apparently just one Guillain-Barre death, in the northwestern Venezuela state of Zulia in January.
Dr. Maria Lucia Brito Ferreira, chief neurologist at Hospital da Restauracao in Recife, Brazil, said she hopes to get laboratory confirmation this month that nine Guillain-Barre deaths recorded there in the past year were Zika-related.
Cases of Guillain-Barre in Colombia — about 450 annually before Zika struck — were up nearly threefold in the past month and a half.
El Salvador has reported 118 cases since November, nearly as many as previously seen in a year. “The only explanation is the Zika virus,” said Deputy Health Minister Eduardo Espinoza.
Dr. Osvaldo Nascimento, a leading Rio neurologist, estimates Brazilian cases of Guillain-Barre are up fivefold. Reporting is not compulsory, so the government’s partial figure of 1,868 cases requiring hospitalization last year is a sketchy parameter.
An upsurge in Guillain-Barre was documented in 2013 during a major Zika outbreak in French Polynesia, with a study finding cases up twentyfold. WHO said all 42 cases recorded in the Pacific archipelago tested positive for Zika as well as dengue fever, which is also currently present in Colombia, Venezuela, Brazil and other Zika-affected countries.
Antibodies for the dengue and chikungunya viruses, which are far more debilitating than Zika, are often being found in infected patients. That is making establishing a direct Zika-Guillain-Barre link more complicated.
Like Zika, both viruses are transmitted by the Aedes aegypti mosquito and could also trigger Guillian-Barre, experts say.
Under normal circumstances, eight in 10 patients nearly fully recover from Guillian-Barre, though it sometimes takes months.
Data on Guillain-Barre is scant in most of the developing world. Of 18 countries participating in a clinical study launched by Dutch physicians in 2012, only two are in Latin America: Mexico and Argentina. Brazil just joined.
Across the region, investigators were simply unable to get government funding to participate, said Dr. Ken Gorson, a Tufts University neurologist and president-elect of an international foundation that combats Guillain-Barre.
Poorer countries were ill-prepared to manage the crisis.
Colombia’s National Health Institute is overwhelmed with a weeks-long backlog in completing tests for Zika.
The three Guillain-Barre deaths that the country’s Health Ministry attributed to Zika on Feb. 5 have not yet been confirmed by laboratory tests, said spokesman Ricardo Amortegui. Nor have the three deaths in the Venezuelan state of Lara announced last week.
One Guillian-Barre fatality in Colombia suspected of being linked to Zika was a 51-year-old man from the Caribbean island of San Andres who died in November, said Rita Almanza, epidemiology chief in Medellin. The others were a 45-year-old man and a 41-year-old woman flown from Turbo on the Caribbean coast who died in Medellin in February.
Guillain-Barre grabbed hold of Nancy Pino in neighboring Venezuela with devastating effect.
The 68-year retired school administrator developed fever, rashes and muscle pain while celebrating Christmas with her family in the hot lowland state of Anzoategui.
She recovered quickly. Days later, her hands and feet started to go numb. Her tongue felt like it was asleep. She stopped eating.
The family rushed her to a Caracas hospital. She could barely walk.
Bed-ridden, she lost the ability to talk and soon, to breathe. Doctors attached her to a respirator.
“It was so quick,” daughter Nihara Ramos said between sobs. “It was like a flame consuming her from the bottom up.”
Doctors diagnosed Guillain-Barre with a spinal tap — they assumed she had Zika earlier — and suggested that the relatives obtain immunoglobulin, an expensive treatment that pools healthy antibodies from hundreds of donors. Gorson said it costs $15,000-$45,000 in the United States.
The family, straightjacketed by Venezuela’s economic crisis, couldn’t find or afford enough.
In less than three weeks, a woman who once bounded up seven flights of stairs to her apartment was dead.
___
Associated Press writer Frank Bajak reported this story from Lima, Peru, and AP writer Libardo Cardona reported in Cucuta, Colombia. AP writers Hannah Dreier in Caracas, Venezuela; Marcos Aleman in San Salvador, El Salvador; and Luis Henao in Santiago, Chile, contributed to this report.
Positive mention in Access Wire this morning:
Nothing new but shows that good word on ASTI is spreading.
http://finance.yahoo.com/news/micro-cap-worthy-mentions-tuesday-150300469.html
Micro Cap Worthy Mentions Tuesday February 16 2016
Ascent Solar Technologies Announced Major Breakthrough in Solar Cell Performance for Space and Near-Space Environments (NASDAQ: ASTI), a developer and manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into the Company's EnerPlex(TM) series of consumer products, announced on Feb 8 2016 the Company has achieved a major breakthrough in power-to-weight ratio for its superlight solar module, delivering over 1700 watts of power per kilogram, operating at AM0, technically known as the space environment. At this performance, Ascent's superlight module would weigh 66% less than a comparable PV system using the highest-quality crystalline silicon and with far less design complexity. The elimination of two-thirds of the weight is a critical improvement for satellites, space vehicles and space stations.
Larvicide True Cause Of Brazil's Microcephaly Outbreak
Interesting article from Tech Times
Enjoy dp
http://www.techtimes.com/articles/133548/20160214/monsanto-larvicide-not-zika-virus-true-cause-of-brazils-microcephaly-outbreak-doctors.htm
Larvicide Manufactured By Sumitomo, Not Zika Virus, True Cause Of Brazil's Microcephaly Outbreak: Doctors
By Alyssa Navarro, Tech Times | February 14, 8:58 AM
A group of Argentine physicians claim that the sudden microcephaly outbreak in Brazil was not caused by the Zika virus, but by a larvicide injected into the country's water supplies.
(Photo : Mario Tama | Getty Images)
The microcephaly outbreak in Brazil, which coincided with the spread of the Zika virus, continues to stun the world, even months after the incident was first reported.
Pregnant women all over the world have been advised to take caution. The Zika virus infection has been linked to newborn babies with the birth defect microcephaly. This is a congenital condition in which babies are born with unusually tiny heads.
The notion, however, has recently been challenged by a group of Argentine physicians. The group suspects that the Zika virus is not to blame for the rise in microcephaly cases, but that a toxic larvicide introduced into Brazil's water supplies may be the real culprit.
Not A Coincidence?
According to the Physicians in Crop-Sprayed Towns (PCST), a chemical larvicide that produces malformations in mosquitoes was injected into Brazil's water supplies in 2014 in order to stop the development of mosquito larvae in drinking water tanks.
The chemical, which is known as Pyriproxyfen, was used in a massive government-run program tasked to control the mosquito population in the country. Pyriproxyfen is a larvicide manufactured by Sumitomo Chemical, a company associated [PDF] with Monsanto. However, PCST has referred to Sumitomo as a subsidiary of Monsanto.
"Malformations detected in thousands of children from pregnant women living in areas where the Brazilian state added pyriproxyfen to drinking water is not a coincidence," the PCST wrote [pdf] in the report.
For instance, the Brazilian Health Ministry had injected pyriproxyfen to reservoirs in the state of Pernambuco. In the area, the proliferation of the Aedes aegypti mosquito, which carries the Zika virus, is very high, the PCST said.
Pernambuco is also the first state in Brazil to notice the problem. The state contains 35 percent of the total microcephaly cases in the country.
The group of Argentine doctors points out that during past Zika epidemics, there have not been any cases of microcephaly linked with the virus. In fact, about 75 percent of the population in countries where Zika broke out had been infected by the mosquito-borne virus.
In countries such as Colombia where there are plenty of Zika cases, there are no records of microcephaly linked to Zika, the group said.
When the Colombian president announced that many of the country's citizens were infected with Zika but that there was not a single case of microcephaly, the allegations soon emerged. Some 3,177 pregnant women in the country were infected with Zika, but the PCST report said these women are carrying healthy fetuses or had given birth to healthy babies.
Remain Skeptical
On its website, Sumitomo Chemical says pyriproxyfen poses minimal risk to birds, fish and mammals.
However, the evidence is overwhelming. The Washington Post reported in January that after experts examined 732 cases out of 4,180 Zika-related microcephaly, more than half were not related to Zika at all. Only 270 cases were confirmed as Zika-linked microcephaly.
On top of all the suspicions, however, the World Health Organization (WHO) has been careful not to explicitly link Zika to microcephaly.
"Although a causal link between Zika infection in pregnancy and microcephaly — and I must emphasize — has not been established, the circumstantial evidence is suggestive and extremely worrisome," said WHO General Director Margaret Chan.
In the meantime, scientists are currently racing toward developing a vaccine for the mosquito-borne infection.
While there is no solid proof yet that the larvicide causes microcephaly, the local government of Grande do Sul in the southern portion of Brazil suspended the use of the chemical larvicide pyriproxyfen.
A Monsanto representative reached out to Tech Times to clarify that the company does not sell or manufacture pyriproxyfen.
"Neither Monsanto nor our products have any connection to the Zika virus or microcephaly. Monsanto does not manufacture or sell Pyriproxyfen. And, Monsanto does not own Sumitomo Chemical Company. It is, however, a business partner like others in the area of crop protection," the representative said.
QLTI acquires 7.2 million ARLZ shares @ $6.25 per
From Feb 5th. Shows ARLZ at today's price of $5.63 is trading at a major discount.
Best to all longs. Enjoy dp
http://www.marketwatch.com/story/qlt-announces-closing-of-acquisition-of-shares-of-aralez-pharmaceuticals-inc-and-special-distribution-to-shareholders-2016-02-05
QLT Announces Closing of Acquisition of Shares of Aralez Pharmaceuticals Inc. and Special Distribution to Shareholders
Published: Feb 5, 2016 1:30 p.m. ET
VANCOUVER, British Columbia, Feb 05, 2016 (GLOBE NEWSWIRE via COMTEX) --
QLT Inc. QLTI, -0.41% (QLT) ("QLT") today announces that it has acquired 7,200,000 common shares (the "Aralez Shares") of Aralez Pharmaceuticals Inc. ()Aralez") for a per share price of US$6.25 and an aggregate purchase price of US$45 million. Aralez is a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. which completed today. Commencing on or about February 8, 2016, the common shares of Aralez will trade on NASDAQ under the ticker symbol "ARLZ", and on or about February 10, 2016, will trade on the Toronto Stock Exchange under the ticker symbol "ARZ". In connection with QLT's acquisition of the Aralez Shares, Jason Aryeh, the Chairman of QLT's board of directors, has been appointed to the board of directors of Aralez.
Special Distribution
As previously announced, QLT intends to distribute the Aralez Shares to its shareholders as a special distribution (the "Special Distribution"). In connection with the Special Distribution, QLT has entered into an agreement with third parties to purchase a certain number of Aralez Shares from QLT at US$6.25 per share so that QLT shareholders will be given the opportunity to elect to receive, in lieu of Aralez Shares, up to an aggregate of US$15 million in cash, subject to proration among the shareholders.
QLT intends to implement the Special Distribution as part of a reorganization of its share capital pursuant to a statutory plan of arrangement (the "Share Reorganization"). The Share Reorganization requires the approval of the QLT shareholders which will be sought at a special meeting ()Special Meeting") of the Company's shareholders scheduled to be held on March 18, 2016 in Vancouver, Canada. If approved at the Special Meeting, the Share Reorganization is expected to permit QLT to make the Special Distribution to QLT shareholders in a tax efficient manner. If the Share Reorganization is not approved at the Special Meeting, the board of directors of QLT may implement the Special Distribution as a dividend in kind.
Record Date for Election and Election Process
QLT's shareholders as of February 16, 2016, the record date for the Special Distribution (the "Record Date") will receive approximately 0.13629 of an Aralez Share for each QLT common share ()QLT Share") held based on the current number of issued and outstanding QLT Shares, subject to the cash election described below. No fractional Aralez Shares will be issued and the number of Aralez Shares distributable pursuant to the Special Distribution will be rounded down to the nearest whole Aralez Share.
QLT shareholders will be entitled to elect to receive all or part of their entitlement of the Special Distribution in cash, subject to proration among the shareholders to reflect the maximum available cash component of US$15 million. The final amount of Aralez Shares (or cash in lieu) payable in respect of each QLT Share will be based on the number of issued and outstanding QLT Shares on the Record Date.
In order to elect to receive cash in lieu of all or part of their entitlement to Aralez Shares, QLT shareholders are required to complete and return an election form which will be mailed on or about February 18, 2016 to registered QLT shareholders as of the Record Date. The election form must be returned to QLT's transfer agent Computershare Investor Services Inc. on or before the deadline which will be set out in the election form. Shareholders who hold QLT Shares through a broker or intermediary should contact their broker or intermediary for details on how to make the election.
Full details of the Special Distribution and the election procedure will be contained in the Proxy Statement to be prepared by QLT and mailed to its shareholders in connection with the Special Meeting. It is anticipated that the Proxy Statement, the election form and other materials will be mailed to QLT shareholders on or about February 18, 2016. Following the mailing to QLT shareholders, the Proxy Statement, the election form and accompanying materials will also be available on QLT's profile at www.sedar.com and www.sec.gov, as well as QLT's website at www.qltinc.com.
Due Bill Trading Procedures
In accordance with the rules of the Toronto Stock Exchange and NASDAQ, "due bill" trading procedures will be applied in connection with the Special Distribution. Pursuant to these procedures, automated systems will track any trading of QLT Shares in the period (the "Due Bill Period") between the second trading day prior to the Record Date for the Special Distribution, being February 11, 2016, and the payment date for the Special Distribution, anticipated to be on or about March 22, 2016 ()Distribution Date"). During the Due Bill Period, automated systems will attach "due bill" instruments to any QLT Shares sold which will obligate sellers to deliver Aralez Shares they are entitled to pursuant to the Special Distribution (or cash in lieu of all or part of their entitlement to Aralez Shares, if an election is made as described above), to buyers of such QLT Shares. Accordingly, if a QLT shareholder sells its QLT Shares during the Due Bill Period, it will be selling away its right to receive the Aralez Shares it is entitled to pursuant to the Special Distribution (or cash in lieu of all or part of its entitlement to Aralez Shares) and such sale will include an obligation on the part of the seller, in the form of a "due bill", to deliver such Aralez Shares or cash in lieu to the buyer of such QLT Shares. It is anticipated that the buyers of QLT Shares during the Due Bill Period will not know whether a cash election has been made with respect to their entitlement to the Special Distribution.
As described above, holders of QLT Shares, including the buyers of QLT shares, on the Distribution Date will be entitled to receive the Special Distribution. The QLT Shares will commence trading on an "ex-distribution" basis on the next trading day following the Distribution Date, as of which date purchases of QLT Shares will no longer have an attaching right to the Special Distribution. The "due bills" will be redeemed once all trades with attached "due bills" entered during the Due Bill Period have settled, which is anticipated to occur at the end of the business day on or about March 29, 2016.
Canadian Early Warning Reporting Requirements
The following disclosure is required by Part 3 of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of the Canadian Securities Administrators. A copy of the report filed by QLT in connection with the acquisition of the Aralez Shares will be filed on Aralez's SEDAR profile, at www.sedar.com. It can also be obtained directly from QLT by contacting Dori Assaly, QLT's Corporate Secretary and Senior Vice President, Legal, at (604) 707-7000.
As set out above, QLT today acquired ownership and control over the Aralez Shares, which represent 10.1% of Aralez issued and outstanding common shares. Immediately prior to the closing of the business combination of Tribute Pharmaceuticals Canada Inc. ("Tribute") and POZEN Inc., QLT acquired common shares of Tribute which were subsequently exchanged for Aralez Shares as a result of the business combination transaction. The Aralez Shares were acquired pursuant to the prospectus exemption contained in Section 2.11 of National Instrument 45-106 Prospectus Exemptions of the Canadian Securities Administrators at a price per Aralez Share of US$6.25 (C$8.58). QLT acquired the Aralez Shares for investment purposes and intends to distribute the Aralez Shares to QLT shareholders pursuant to the Special Distribution, as described above. QLT may acquire further securities of Aralez for investment purposes, in the market or privately, from time to time.
About QLT
QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.
QLT's head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ Stock Market (symbol:QLTI) and the Toronto Stock Exchange (symbol:QLT). For more information about the Company's products and developments, please visit our website at www.qltinc.com.
GhostInTheMatrix:
Thanks for this Zika virus IHUB message board. Below is some basic DD on Aethlon Medical (NASDAQ - AEMD) as you requested hopefully to be added to the ZIKA virus (Shorts and Longs) (ZIKA) message board.
I urge all here to explore Aethlon Medical at the links provided below.
Thanks again. Best to all here. Enjoy dp
AEMD- Aethlon Medical - http://www.aethlonmedical.com/
About The Aethlon Hemopurifier®
Of the hundreds of viruses known to be infectious to man, antiviral drug therapies are approved for fewer than ten. The Aethlon Hemopurifier® provides a broad-spectrum therapeutic strategy to address drug resistant viral pathogens. To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus (Ebola), Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). Time Magazine recently named the Hemopurifier to their list of “Top 25 Inventions" and "The 11 Most Remarkable Advances in Healthcare." Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the capture of some of world’s deadliest pathogens. These include: Dengue hemorrhagic virus, Lassa hemorrhagic virus, H5N1 avian influenza virus, H1N1 swine flu virus, the reconstructed 1918 influenza virus, West Nile virus, Zika virus and Vaccinia and Monkeypox, which serve as models for human smallpox infection. U.S. clinical progression of Hemopurifier therapy is being advanced under FDA approved clinical studies.
Aethlon is also investigating the use of Hemopurifier therapy to capture tumor-derived exosomes, a significant unaddressed therapeutic target in cancer care. Tumor-derived exosomes promote cancer progression through multiple mechanisms, which include seeding the spread of metastasis and direct suppression of the immune response.
Link to most recent webcast at Source Capital Conference on Feb 10, 2016 in New York City:
http://wsw.com/webcast/sourcecap1/aemd/index.aspx
New SEC Form PRE 14A filed on February 12, 2016
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=10740904&type=HTML&symbol=AEMD&companyName=Aethlon+Medical+Inc&formType=PRE+14A&dateFiled=2016-02-12&cik=0000882291
Best extended Weekend to all. Northerner's - STAY WARM!
Enjoy dp
Way too Much Fear of the unknown here
When in actuality, the Process is a Known and Legal Procedure.
Try and Get a Grip Guys. Imagining just doesn't Work so Good.
Best weekend to all. Enjoy dp
Latest Current ASTI Status
Noncompliant Companies:
Ascent Solar Technologies, Inc.
Sym Deficiency Market Notification Date
ASTI Bid Price NCM 6/18/2015
ASTI Market Value NCM 6/9/2015
Issues Pending Suspension or Delisting:
ASTI - NOT LISTED
Short Sale Circuit Breaker from yesterday: Restricted
SPHS Sophiris Bio, Inc. Common Stk R 2/11/2016 9:32:29 AM
http://www.nasdaqtrader.com/trader.aspx?id=ShortSaleCircuitBreaker
Most likely (99.9%) is your "guy" knows nothing
He's just upset maybe you disturbed his lunch order, breakfast or something similar. Why would he be upset no matter what the reality of your stock was? Generally, they couldn't give a rats a$$. That's all up to you.
The "R" from yesterday identifies ASTI as Restricted under the Short Sale Circuit Breaker
ASTI Ascent Solar Tech Cmn Stk R 2/11/2016 11:41:47 AM
http://www.nasdaqtrader.com/trader.aspx?id=ShortSaleCircuitBreaker
When something is announced everyone will know.
Best to you dp
MM and flippers can't make any money
if the stock just sits there stagnant so it's in their best interest that it moves and dances around a bit...
Isn't that what it's all about? LOL
Enjoy dp
ARLZ to Ring The Nasdaq Stock Market Closing Bell Today
ADVISORY, Feb. 12, 2016 (GLOBE NEWSWIRE) --
What:
Aralez Pharmaceuticals Inc. (ARLZ), a global speciality pharmaceutical company, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Adrian Adams, Chief Executive Officer, will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Tuesday, February 16, 2016 – 3:45 p.m. to 4:00 p.m. ET
Still listed as Noncompliant and NOT Pending Suspension or Delisting
Best to all longs dp
Concussion doctor thinks O.J. Simpson might have CTE
With the BU CTE paper being published soon, OJ series on TV and the possibility that he has CTE currently raised in the News this is the perfect time for Exosome Sciences CTE diagnosis to get involved and get some wide spread publicity. Just an offer to test OJ would bring a lot of attention to Exosome Sciences, their CTE Diagnostic Test along with getting Aethlon Medical into the greater public eye.
The time to strike is when the iron is hot...
Enjoy dp
http://www.ew.com/article/2016/01/28/concussion-doctor
Concussion doctor thinks O.J. Simpson might have CTE
When disgraced football Hall of Famer O.J. Simpson was facing trial on armed robbery and kidnapping charges of which he was convicted in 2008, he considered using the defense that concussions he allegedly sustained during his 11 years in the NFL could have contributed to his actions.
As more research and information come to light regarding the degenerative neurological damage that occurs with repeated blows to the head, the idea that Simpson could actually be suffering from chronic traumatic encephalopathy, or CTE — the debilitating brain disease caused by brain trauma that has been linked to football players — has gained traction.
Among those who believe Simpson suffered from CTE is Dr. Bennet Omalu, the world-renowned forensic pathologist who first identified the disease in football players.
“I would bet my medical license that he has CTE,” Omalu, who inspired the movie Concussion, starring Will Smith, tells PEOPLE exclusively.
Those suffering from the disease, which can only conclusively be confirmed after death by testing cross sections of brain tissue, exhibit a wide range of symptoms. These include mood swings, unjustified violent tendencies, domestic violence, criminality and exaggerated emotional reactions to every day stresses.
“Given his profile,” adds Omalu, “I think it’s not an irresponsible conclusion to suspect he has CTE.”
Simpson Cited ‘Numerous Blows to My Head’ in 2012 Court Docs
Simpson, who won the Heisman Trophy in college and became the first NFL player to rush for more than 2,000 yards in a season, endured thousands impacts to the head during his playing career. But there’s another factor that could plausibly make his brain even more susceptible to the disorder: He possessed what is rumored to be one of the biggest heads in the NFL, one so large he required custom-made helmets.
“If you have a bigger head that means your head is heavier,” explains Omalu. “That means the momentum of your impact would be bigger. It’s basic physics.”
In 2012, Simpson tried to convince a Clark County Nevada judge that he suffered from some sort of concussion-related brain damage. At that time, he and his lawyers were attempting to get a new trial following his 2008 conviction for armed robbery in Las Vegas — 13 years to the day after being acquitted of the murders of Nicole Brown Simpson and Ronald Goldman.
During the initial stages of the proceedings, he and his attorney reportedly filed a sworn statement in court outlining his history of brain injuries. In the document, Simpson stated that he sustained “numerous blows to my head and/or landed on my head violently” while playing in the NFL and at USC.
Simpson added, “I was knocked out of games for such head blows repeatedly in the 1970s and other times I continued playing despite hard blows to my head during football games.”
Former Business Manager: ‘There’s Something Wrong With His Head and There Has Been For a Long Time’
Simpson’s attorney eventually abandoned this legal strategy, but the idea that he could be suffering from CTE is something that at least some of the people still in Simpson’s life take seriously.
“Everybody who knows him knows there’s a problem there,” says his former business manager Norman Pardo, who has visited Simpson at the Nevada prison where he’s incarcerated. “There’s something wrong with his head and there has been for a long time.”
Simpson was sentenced to 33 years in prison, but will be up for parole in 2017. Whether he actually suffers from CTE or not would not have mattered in that Nevada courtroom in 2012, says former federal prosecutor Stanley L. Friedman, a Los Angeles-based attorney.
“It might affect his punishment, but not his culpability,” explains Friedman. “If someone has diminished capacity, he can still be responsible for the crime. It’s more an argument in mitigation in terms of a sentence.”
If Simpson in fact suffers from CTE, he may finally be facing the one sentence that no lawyer in the world can help him beat.
“That’s something I’ve wondered about for years,” says the widow of a former top NFL player who not only knew Simpson – but watched CTE slowly ravage her husband. “You just cannot tell me that O.J. isn’t afflicted by this.”
2016 Disruptive Growth & Healthcare Conference
AEMD - Wednesday, February 10, 2016
2:15pm EST
Convene
730 Third Avenue (bet 45th / 46th Streets)
New York, NY
Webcast replay available at link below.
Best to all in this bloodbath of a market. dp
http://aethlonmedical.investorroom.com/index.php?s=19
Isn't anyone overly curious Why?
Sachs Investment Group initiated a whales position of 746,205 shares (9.8% of outstanding shares) when all they are is a little fish?
I know I was. Funny... don't you Think? or just Not thinking??
And BTW, IMHO it was a Very Good Presentation today.
Enjoy dp
While many here are quibbling over pennies...
The reality is that the Ascent Solar light weight solar panels for outer space have the potential to launch ASTI share price into outer space along with their flexible Solar PV Panels.
Excerpt: ....Yet one obstacle has seemed insurmountable: the cost to get up to 10,000 tons of components all the way to geosynchronous orbit. Rockets today are not reusable, and that makes them so expensive — currently around $4,600 for each kilogram of payload lofted into low orbits — that the economics of putting solar modules in space just don’t pencil out, even if the modules use solar-electric propulsion to lift themselves into their final orbit. For stellar power to compete with other kinds of renewable energy, those costs need to drop to around $400 a kilogram, Mankins estimates. Rocket launches would have to become a lot more frequent as well. Building a large plant would require hundreds of launches a year....
See the whole article at the link below:
The Promise of Space-Based Solar Panels -
Solar satellites could deliver clean, abundant power — if they get off the ground.
http://discovermagazine.com/2015/july-aug/19-stellar-energy
Nothing weak about this PR!
Weight, performance and durability are everything up in the air and in space. Ascent Solar is well positioned for exponential future growth.
http://finance.yahoo.com/news/200-million-order-industrial-commodities-133000639.html
After a 97% drop over the past 12 months, Ascent Solar Technologies, Inc. (ASTI) has seen an almost 83% increase from it's low of $.06 only 10 days ago. Ascent develops and manufactures state of the art flexible thin film photovoltaic modules integrated into their EnterPlex series of consumer products.
Ascent just announced a breakthrough in power to weight ratio for its superlight solar module. At comparable performance, Ascent's module would weigh 66% less than its peers. This is a 2/3 weight reduction which is critical for satellites, space vehicles and space stations where power to weight ratio is key.
SPHS is chock full of experienced proven talent
I'm a big fan of our Chairman of the Board Lars Ekman, MD, PhD.
Lars has more than 30 years in senior executive, scientific, and clinical functions, as well as several clinical and academic positions in both the United States and Europe. Lars joined Sofinnova Ventures in 2008 as an Executive Partner to lend his extensive Life Science experience to the investment team in driving new companies toward success.
Dr. Ekman is Chairman of Amarin Corporation plc (AMRN), Chairman of Sophiris Bio, Inc. (SPHS), Chairman of Prothena Corporation plc (PRTA), and Chairman of Poseida Therapeutics. He also serves as a director of Spark Therapeutics, Inc. (ONCE).
Prior to joining Sofinnova Ventures, Lars held the position of President of Research and Development at Elan. He joined Elan in January 2001, and he is credited with advancing Elan's drug discovery pipeline during this period. Under his leadership, Elan received approval for four U.S. New Drug Applications, three European Marketing Approval Applications, and five Investigational New Drug Applications. These efforts resulted in advancing Elan’s immunotherapeutic approach into Phase III and bringing to market three innovative neuroscience based products, including Tysabri for MS. Prior to joining Elan, he was EVP, Research and Development at Schwarz Pharma AG beginning in 1997. From 1984 to 1997. From 1984 to 1997, Dr. Ekman was employed in a variety of senior scientific and clinical functions at Pharmacia, now Pfizer.
Lars is a board-certified surgeon with a PhD in Experimental Biology and has held several clinical and academic positions in both the United States and Europe. He obtained his PhD and MD from the University of Gothenburg, Sweden.
http://www.sofinnova.com/team_detail.php?sort=all&id=40
and of course also Dr Allison Hulme
Dr. Hulme has been our Chief Operating Officer and Head of Research and Development since April 2011, and she brings over 20 years of drug development experience to the company. From January 2005 to October 2009, Dr. Hulme served as Executive Vice President of Autoimmune, Tysabri, Global Development and Head of Autoimmune and Tysabri Franchise at Elan Corporation, plc (also known as Elan Pharmaceuticals), a neuroscience-focused biotechnology company. She served as Executive Vice President and head of global development at Elan Pharmaceuticals from October 1995 to January 2005. Previously, Dr. Hulme held several positions in clinical research at Glaxo Wellcome Pharmaceuticals and served as lecturer at Luton University. Dr. Hulme holds a first class honors Degree in Science from Luton University and a Ph.D. from Cranfield Institute of Technology.
Both that I got to see in action at Elan Pharmaceuticals.
Hard to find a Company with management more talented, experienced and well rounded as Sophiris Bio at any price but especially at this low market cap with advanced clinicals in such major dollar and marketable indications
Best to all. Enjoy! dp
Learn Why Sachs Investment Group Just Purchased Aethlon Medical Inc Stake?
Passive and Active Investment News
February 8, 2016 By Patrick Sproles
http://www.fdanewsalert.com/learn-why-sachs-investment-group-just-purchased-aethlon-medical-inc-stake/854758/
The New Sachs Investment Group Holding in Aethlon Medical Inc
Sachs Investment Group filed with the SEC SC 13G/A form for Aethlon Medical Inc. The form can be accessed here: 000108514616002818. As reported in Sachs Investment Group’s form, the filler as of late owns 9.8% or 746,205 shares of the Health Care–company.
Aethlon Medical Inc stake is a new one for the and it was filed because of activity on December 31, 2015. We feel this shows Sachs Investment Group’s positive view for the stock.
Business Profile
Aethlon Medical, Inc. is a medical device company, which creates medical devices to address unmet therapeutic needs in infectious disease, cancer and other life-threatening conditions. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are secreted by tumors to prevent the immune system from rejecting the tumors. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based products to diagnose and monitor neurological disorders and cancer. Additionally, the Company operates under two Department of Defense contracts related to a program entitled Dialysis-Like Therapeutics.
SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.
About 18,343 shares traded hands or 4.84% up from the average. Aethlon Medical, Inc. (NASDAQ:AEMD) has declined 28.99% since July 2, 2015 and is downtrending. It has underperformed by 19.51% the S&P500.
According to Zacks Investment Research, “Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system’s response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.”
Additional Info:
http://listings.findthecompany.com/l/7929169/Aethlon-Medical-Inc-in-San-Diego-CA
Thanks for setting this up EI
Best to all "Ground Floor" investors. May we grow and prosper.
Enjoy! dp
Anyone have any insight on this:
Sachs Investment Group - OWNERSHIP
(a) Amount beneficially owned: 746,205 shares
(b) Percent of class: 9.8%
Is this a new position? I don't see any previous filings on record.
Have they just initiated this 3.5 (+) million dollar investment & 1st time disclosure?
I find this very curious for obvious and other reasons.
TIA dp
New 13 G just released
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=10717461&type=HTML&symbol=AEMD&companyName=Aethlon+Medical+Inc&formType=SC+13G%2FA&dateFiled=2016-02-08&cik=0000882291
Sachs Investment Group - OWNERSHIP
(a) Amount beneficially owned: 746,205 shares
(b) Percent of class: 9.8%
More Shots on Goal for Hemopurifier, ESI
FWIW New Zacks Research Report out this morning:
http://finance.yahoo.com/news/aemd-more-shots-goal-hemopurifier-144500837.html
And YES, it's way past time for JJ to bring in someone or partner with a Company that can and will bring things to market and not just be a Not For Profit Research - Forever entity. Doesn't seem like he has either the required motivation or know how to make that happen and that is what is required NOW!
Too many failed opportunities to capitalize on situations layed right in Aethlon's lap without seeing any sufficient marketing progress.
dp
Enerplex Kicker II durability test:
Shoot it with a handgun, a shotgun and then run it over with your truck, and it just keeps on charging.
Try that with the competitions products and see the difference.
Agree porky but it's either one or the other
It's either or a Trading vehicle or an Investing vehicle.
IMHO It's hard for a Company in this precarious of a position to be good at both share price wise.
Enjoy dp
Regarding the incredible repetitive ASTI VOLUME
When you consider all the ASTI "investors" that Buy - Sell & Flip on a minute to minute, hour by hour or daily basis it's no wonder that the share trading volume is so high and the share price keeps surging back and forth without being able to make or keep any headway.
Most of the complaints here blame the Company when in reality much of the fault probably comes from those that are complaining while doing all the flipping under the guise of being ASTI "investors". In reality - They actually are NOT investors. What they are is opportunistic flippers.
Want to complain to someone Why ASTI hasn't been able to build share price and hold a rebound? I think many of you should just Blame yourselves instead of looking to someone else for what is in reality, partly your own doing.
Enjoy dp
The difference between MM and ECN / NDD / STP brokers
Thanks for all your input and alerts Hei5enberg. Don't know What? is happening with all those trades but do know that many of the larger trades others see don't show up on my Etrade charts.
Best to you dp
http://feedback.tradeinterceptor.com/knowledgebase/articles/392594-what-is-the-difference-between-market-makers-and-e
What is the difference between Market Makers and ECN / NDD / STP brokers?
Market makers
Market makers set both the bid and the ask prices and display them on their quote screens. They route orders through their own dealing desk and are prepared to make transactions at the displayed prices, providing liquidity to their clients. A Dealing Desk Forex broker also called a Market Maker literally ”makes the market” for traders: when traders want to sell, they buy from them, when traders want to buy, they sell to them, meaning they take the opposite side of the trade. Traders don’t see the real market quotes and the broker makes money via spreads - which are generally fixed spreads.
NDD - No Dealing Desk
NDD Forex brokers provide access to the interbank market without passing orders through their dealing desk. With true No Dealing Desk brokers there are no re-quotes on orders and no additional pausing during order confirmation. A NDD broker can either charge a commission for trading or choose to increase the spread and make Forex trading commission free. No Dealing Desk brokers are either STP or ECN+STP.
STP - Straight Through Processing
STP Forex brokers send orders directly from clients to the liquidity providers - banks or other brokers. Sometimes STP brokers have just one liquidity provider, other times several. The more the liquidity providers - and therefore liquidity in the system - the better the fills for the clients. The fact that traders have access to the real-time market quotes and can execute trades immediately without dealer intervention is what makes the platform STP.
ECN - Electronic Communications Network
ECN brokers pass on prices from multiple market participants, such as banks and market makers, as well as other traders connected to the ECN, and display the best bid/ask quotes on their trading platforms based on these prices. ECN Forex brokers additionally allow orders to interact with other orders. They provide a marketplace where all participants (banks, market makers and individual traders) interact inside the system and get the best offers for their trades available at that time. Unlike fixed spreads, often offered by market makers, ECNs spreads vary, depending on the pair’s trading activities. During very active trading periods, you can sometimes get no spread at all, particularly in very liquid currency pairs. These brokers make money by charging customers a fixed commission for each transaction. Authentic ECNs do not play any role in making or setting prices, therefore, the risks of price manipulation are reduced for retail traders. True ECN brokers display the Depth of the Market (DOM) showing order sizes in the system.?
Most everyone is too busy...
bleeding.
Best to all. dp
Good link re: Trading Halt info
http://www.nasdaqtrader.com/trader.aspx?id=TradingHaltHistory
SPHS Halt info from that page:
01/28/2016 13:01:41 SPHS Sophiris Bio, Inc. Common Stk NASDAQ LUDP 01/28/2016 13:01:41 13:06:41
Enjoy dp
+90% Increase without any GSA sales included
Wait till Govt. orders start kicking in. EnerPlex products are a Big time winner.
Enjoy dp
Not saying anything besides relaying the agreement
I'm sure there are several ways to look at it while trying to figure out if there is anyway this purchase agreement could be having an influence on the share price.
At this point (under $2) they are not committed to purchase any shares as I read it. I thought that the share price was required to be over $2 for 10 consecutive days for this agreement to be in effect but I have not been able to locate anything to confirm that.
One way to look at it is; If you just consider the $13 million committed to buy shares they would obviously seem to benefit more from a lower (above $2) share price than a higher one for their $13 million worth of purchase's.
@ $2.10 per share = 6.2 million shares
@ $2.50 per share = 5.2 million shares
@ $3.10 per share = 4.2 million shares etc. etc.
So, at this point with the Phase III BPH & Phase II Prostrate cancer trials both indicating positive and "encouraging" results respectively, the $13 million they are committed to purchase could yield an enormous gain and the more shares they have the greater that gain would be. And, as we all know making the most money for your investment is usually what it's all about.
Not saying they are doing anything either improper or even relating to this possibility (or how?? they could actually do it) but, it sure seems like they would stand to benefit greatly from a lower (above $2) share price than the runaway train price we saw after the Phase II News Release on Thursday.
Just a thought and appreciate all opinions on the subject of Why?? share price is at $1.93 after that positive News.
Enjoy dp
Painting the tape at close with a few shares so the price is in the proper range to start the process all over again next trading day is how I see it.
I believe they call it manipulation. LOL
>>And who just bumped up the price after hours to .075 on 1050 shares? Why so many games?<<
I'm wondering whether the information below could have anything to do with what we saw happen to share price yesterday (the rapid retraction) and why the share price is currently sitting under $2 which to me just doesn't seem to reflect a proper valuation considering the clinical trial findings just announced:
http://www.businesswire.com/news/home/20150310005288/en/Sophiris-Bio-Reports-Fourth-Quarter-Full-Year
March 10, 2015 04:05 PM Eastern Daylight Time
SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three months and year ended December 31, 2014.....
In May 2014, Sophiris announced it entered into a common stock purchase agreement with Aspire Capital to support the proof of concept study of PRX302 in prostate cancer. Aspire made an initial purchase of 604,320 common shares at $3.31 per share for proceeds of $2 million and committed to purchase up to $13 million in additional shares over the next 30 months at prices based on market price at the time of purchase and subject to a $2.00 floor price.
Anyone able to elaborate with additional information relating to this stock purchase agreement and whether it could possibly have anything to do with negatively influencing the current (below $2) share price and perceived low evaluation. I have absolutely no idea other than the information supplied above and questioning Aspire's possible motivation.
Thanks in advance and Best to all Longs.
Enjoy! dp